- ►annals.org [PDF] PJ Stiff, J Veum-Stone, HM Lazarus, L Ayash … - Annals of internal medicine, 2000 - Am Coll Physicians Background: Autologous transplantation is increasingly used to treat epithelial
ovarian cancer. However, it is not clear which patients may benefit. Objective:
To determine overall and progression-free survival and factors associated ... Cited by 54 - Related articles - BL Direct - All 5 versions
H Cure, C Battista, JP Guastalla, M Fabbro, N … - Journal of Clinical Oncology, 2004 - Am Soc Clin Oncol Background: Phase II studies have suggested that HDC is most effective in
chemosensitive AOC pts with low tumor burden. Methods: We compared the disease
free-survival (DFS), overall survival (OS) and toxicity of women with AOC ... Cited by 54 - Related articles - All 2 versions
F Bertucci, P Viens, JR Delpero, VJ Bardou, … - Bone marrow transplantation, 2000 - ncbi.nlm.nih.gov The importance of dose intensity has been suggested in ovarian carcinoma. We
retrospectively evaluated the long-term results of melphalan-based high-dose
chemotherapy (HDC) with hematopoietic rescue in a unicentric series of 33 ... Cited by 24 - Related articles - BL Direct - All 3 versions
- ►oxfordjournals.org [PDF] JA Ledermann, R Herd, D Maraninchi, P Viens, … - Annals of Oncology, 2001 - Springer Purpose: to determine the outcome of epithelial ovarian cancer in patients
registered with the European Group for Blood and Marrow Transplantation (EBMT).
Patients and methods: A retrospective analysis was per- formed on 254 ... Cited by 32 - Related articles - BL Direct - All 8 versions
RJ Schilder, MF Brady, D Spriggs, T Shea - Gynecologic Oncology, 2003 - Elsevier Patients and Method. Patients had histologically documented epithelial ovarian
cancer and optimal initial cytoreductive surgery. No prior chemotherapy was
permitted. Adequate performance status, bone marrow, hepatic, and renal ... Cited by 28 - Related articles - BL Direct - All 6 versions
H Wandt, J Birkmann, T Denzel, K Schäfer, G … - Bone marrow transplantation(Basingstoke), 1999 - cat.inist.fr To assess high-dose carboplatin chemotherapy with or without paclitaxel with
filgrastim mobilized peripheral blood progenitor cell(PBPC) support in a phase
I/II study, a total of 21 patients with mostly chemonaive disease received ... Cited by 41 - Related articles - BL Direct - All 3 versions
RJ Schilder, TC Shea - Seminars in oncology, 1998 - ncbi.nlm.nih.gov Recent advances in hematopoietic support have extended the application of
high-dose chemotherapy in the treatment of malignancy. The use of
colony-stimulating factors and peripheral blood progenitor cells ... Cited by 14 - Related articles - BL Direct - All 2 versions
PJ Stiff, EJ Shpall, PY Liu, SP Wilczynski, … - Gynecologic Oncology, 2004 - Elsevier Results. Of 67 randomized, the 32 and 26 eligible in the CMC and CTC arms were
matched including age (median 49), maximum tumor diameter, and disease status at
transplant. Low-risk disease (maximum diameter disease ≤ 0.5 cm and ... Cited by 15 - Related articles - All 3 versions
JP Lotz, C Bouleuc, T André, E Touboul, C … - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 21 - Related articles - BL Direct - All 3 versions
- ►jcojournal.org [PDF] M Legros, J Dauplat, J Fleury, H Cure, F … - Journal of Clinical Oncology, 1997 - jcojournal.org Purpose: A series of 53 patients with poor-prognosis epithelial ovarian cancer
treated with high-dose chemo- therapy (HDC) followed by hematopoietic rescue was
ret- rospectively studied from the day of diagnosis for toxic- ity and ... Cited by 84 - Related articles - BL Direct - All 7 versions
